FIELD: medicine, pharmaceutics.
SUBSTANCE: bifidobacterial consortium contains Bifidobacterium bifidum OV-19, B. bifidum 791, B. longum B379M, B. breve OV-12, B. Mantis 73-15; it is used for preparing bacterial preparations and dietary supplements for correcting the microflora in the children under the age of three. The consortium is high-technology; it stores a biomass on nutrient mediums over a short period of time with a high concentration of probiotic microorganisms, possesses the acid-forming and antagonist properties in relation to the pathogenic and opportunistic microflora. The consortium is prepared by the co-culture of the strains including the length of an exponential growth phase of each of them whereby a priority of the nutrient medium inoculation of the specific composition is determined.
EFFECT: using the consortium as a part of the bacterial preparation for treating the dysbiotic gastrointestinal conditions in the children under the age of three, and the dietary supplement provides the more effective and fast correction of the child's gastrointestinal microflora.
4 cl, 9 tbl, 3 ex
